90
Participants
Start Date
August 8, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
FB825
The study treatment will be administered as 5 SC doses in total 12 weeks
Placebo
The study treatment will be administered as 5 SC doses in total 12 weeks
RECRUITING
UT Health Science Houston, Bellaire
RECRUITING
Center for Clinical Studies, Webster
RECRUITING
California Allergy and Asthma Medical Group, Los Angeles
RECRUITING
First OC Dermatology, Fountain Valley
RECRUITING
Center for Dermatology Clinical Research, Inc., Fremont
RECRUITING
University of California, Davis Health, Department of Dermatology, Sacramento
RECRUITING
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City
RECRUITING
Kaohsiung Veterans General Hospital, Kaohsiung City
RECRUITING
Linkou Chang Gung Memorial Hospital, New Taipei City
RECRUITING
Taipei Medical University-Shuang Ho Hospital, New Taipei City
RECRUITING
China Medical University Hospital, Taichung
RECRUITING
National Cheng Kung University Hospital, Tainan City
RECRUITING
National Taiwan University Hospital, Taipei
RECRUITING
Taipei Mackay Memorial Hospital, Taipei
RECRUITING
Taipei Veterans General Hospital, Taipei
RECRUITING
Tri-Service General Hospital, Taipei
Lead Sponsor
Oneness Biotech Co., Ltd.
INDUSTRY